| MeSH term | MeSH ID | Detail |
|---|---|---|
| Gram-Negative Bacterial Infections | D016905 | 16 associated lipids |
| Angiomatosis, Bacillary | D016917 | 2 associated lipids |
| Meningitis, Bacterial | D016920 | 6 associated lipids |
| Common Variable Immunodeficiency | D017074 | 4 associated lipids |
| AIDS-Related Opportunistic Infections | D017088 | 9 associated lipids |
| IgA Deficiency | D017098 | 2 associated lipids |
| Liver Failure, Acute | D017114 | 11 associated lipids |
| Skin Diseases, Bacterial | D017192 | 8 associated lipids |
| Dermatitis, Phototoxic | D017484 | 4 associated lipids |
| Pityriasis Rosea | D017515 | 3 associated lipids |
| Cutaneous Fistula | D017577 | 1 associated lipids |
| Kleine-Levin Syndrome | D017593 | 1 associated lipids |
| Periodontal Attachment Loss | D017622 | 7 associated lipids |
| Soft Tissue Injuries | D017695 | 2 associated lipids |
| Community-Acquired Infections | D017714 | 8 associated lipids |
| Cytomegalovirus Retinitis | D017726 | 2 associated lipids |
| Tuberculosis, Multidrug-Resistant | D018088 | 6 associated lipids |
| Cardiovascular Abnormalities | D018376 | 2 associated lipids |
| Pneumonia, Bacterial | D018410 | 16 associated lipids |
| Soft Tissue Infections | D018461 | 2 associated lipids |
| Ventricular Dysfunction, Left | D018487 | 33 associated lipids |
| Cryptogenic Organizing Pneumonia | D018549 | 3 associated lipids |
| Carcinoma, Lewis Lung | D018827 | 22 associated lipids |
| Gingival Overgrowth | D019214 | 7 associated lipids |
| Tooth, Nonvital | D019553 | 2 associated lipids |
| alpha 1-Antitrypsin Deficiency | D019896 | 3 associated lipids |
| Genetic Predisposition to Disease | D020022 | 24 associated lipids |
| Neurotoxicity Syndromes | D020258 | 34 associated lipids |
| Central Nervous System Protozoal Infections | D020808 | 3 associated lipids |
| Epilepsy, Partial, Motor | D020938 | 1 associated lipids |
| Chlamydophila Infections | D023521 | 4 associated lipids |
| Desulfovibrionaceae Infections | D045824 | 5 associated lipids |
| Renal Insufficiency | D051437 | 8 associated lipids |
| Immune Reconstitution Inflammatory Syndrome | D054019 | 1 associated lipids |
| Buruli Ulcer | D054312 | 1 associated lipids |
| Extensively Drug-Resistant Tuberculosis | D054908 | 1 associated lipids |
| Leprosy, Paucibacillary | D056005 | 2 associated lipids |
| Upper Extremity Deep Vein Thrombosis | D056824 | 1 associated lipids |
| Acute Kidney Injury | D058186 | 34 associated lipids |
| Plaque, Atherosclerotic | D058226 | 7 associated lipids |
| Sacroiliitis | D058566 | 1 associated lipids |
| Chlamydial Pneumonia | D061387 | 2 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Mosdósi B et al. | Severe acrocyanosis precipitated by cold agglutinin secondary to infection with Mycoplasma pneumoniae in a pediatric patient. | 2017 | Croat. Med. J. | pmid:29308834 |
| Zhang X and Hu C | Selecting optimal columns for clarithromycin impurity analysis according to the quantitative relationship of hydrophobic subtraction model. | 2017 | J Pharm Biomed Anal | pmid:28024686 |
| Addo KK et al. | Genotyping and drug susceptibility testing of mycobacterial isolates from population-based tuberculosis prevalence survey in Ghana. | 2017 | BMC Infect. Dis. | pmid:29197331 |
| Liu W et al. | Rapid detection of mutations in erm(41) and rrl associated with clarithromycin resistance in Mycobacterium abscessus complex by denaturing gradient gel electrophoresis. | 2017 | J. Microbiol. Methods | pmid:29079298 |
| Chang CH et al. | Non-Tuberculous Mycobacteria Infection Following Autologous Fat Grafting on the Face. | 2017 | Aesthet Surg J | pmid:29045552 |
| Paul P et al. | Capillary electrophoresis with capacitively coupled contactless conductivity detection method development and validation for the determination of azithromycin, clarithromycin, and clindamycin. | 2017 | J Sep Sci | pmid:28683179 |
| Kajihara Y et al. | Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication. | 2017 | Scand. J. Gastroenterol. | pmid:27806639 |
| Shaulov A et al. | Progressive refractory light chain amyloidosis and multiple myeloma patients are responsive to the addition of clarithromycin to IMiD based therapy. | 2017 | Am. J. Hematol. | pmid:27804150 |
| Malfertheiner P et al. | Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. | 2017 | Gut | pmid:27707777 |
| Sharifi R et al. | Dietary PUFA Increase Apoptosis in Stomach of Patients with Dyspeptic Symptoms and Infected with H. pylori. | 2017 | Lipids | pmid:28493185 |
| Morimoto K et al. | A Laboratory-based Analysis of Nontuberculous Mycobacterial Lung Disease in Japan from 2012 to 2013. | 2017 | Ann Am Thorac Soc | pmid:27788025 |
| Reddy AB and Reddy ND | Development of Multiple-Unit Floating Drug Delivery System of Clarithromycin: Formulation, in vitro Dissolution by Modified Dissolution Apparatus, in vivo Radiographic Studies in Human Volunteers. | 2017 | Drug Res (Stuttg) | pmid:28449156 |
| Aktas AH and Saridag AM | Liquid Chromatographic-Chemometric Techniques for the Simultaneous HPLC Determination of Lansoprazole, Amoxicillin and Clarithromycin in Commercial Preparation. | 2017 | J Chromatogr Sci | pmid:28449104 |
| Itskoviz D et al. | Smoking increases the likelihood of Helicobacter pylori treatment failure. | 2017 | Dig Liver Dis | pmid:28427781 |
| Koštrun S et al. | Around the macrolide - Impact of 3D structure of macrocycles on lipophilicity and cellular accumulation. | 2017 | Eur J Med Chem | pmid:28410508 |
| Wong AYS et al. | Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis. | 2017 | Drug Saf | pmid:28397186 |
| Baluch A et al. | Successful management of Mycobacterium haemophilum lower extremity cutaneous infection in a matched-unrelated donor stem cell transplant recipient. | 2017 | Transpl Infect Dis | pmid:27775824 |
| Aziz DB et al. | Rifabutin Is Active against Mycobacterium abscessus Complex. | 2017 | Antimicrob. Agents Chemother. | pmid:28396540 |
| Maruyama M et al. | Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Eradication: A Randomized Controlled Trial. | 2017 | Can J Gastroenterol Hepatol | pmid:28349044 |
| Brouqui P et al. | Old antibiotics for emerging multidrug-resistant/extensively drug-resistant tuberculosis (MDR/XDR-TB). | 2017 | Int. J. Antimicrob. Agents | pmid:28336312 |
| Xu YF et al. | and Antibacterial Activities of Patchouli Alcohol, a Naturally Occurring Tricyclic Sesquiterpene, against Helicobacter pylori Infection. | 2017 | Antimicrob. Agents Chemother. | pmid:28320722 |
| Yang YJ et al. | Ten days of levofloxacin-containing concomitant therapy can achieve effective Helicobacter pylori eradication in patients with type 2 diabetes. | 2017 | Ann. Med. | pmid:28266875 |
| Geng X et al. | The Bifunctional Enzyme SpoT Is Involved in the Clarithromycin Tolerance of Helicobacter pylori by Upregulating the Transporters HP0939, HP1017, HP0497, and HP0471. | 2017 | Antimicrob. Agents Chemother. | pmid:28242673 |
| Larsen EL et al. | Clarithromycin, trimethoprim, and penicillin and oxidative nucleic acid modifications in humans: randomised, controlled trials. | 2017 | Br J Clin Pharmacol | pmid:28185274 |
| Ono S et al. | Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin. | 2017 | Helicobacter | pmid:28098408 |
| Gouin-Thibault I et al. | Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. | 2017 | J. Thromb. Haemost. | pmid:27893182 |
| Giguère S et al. | Antimicrobial Resistance in . | 2017 | Microbiol Spectr | pmid:29052538 |
| Park J et al. | Progression and Treatment Outcomes of Lung Disease Caused by Mycobacterium abscessus and Mycobacterium massiliense. | 2017 | Clin. Infect. Dis. | pmid:28011609 |
| Park SM et al. | Randomized clinical trial comparing 10- or 14-day sequential therapy and 10- or 14-day concomitant therapy for the first line empirical treatment of Helicobacter pylori infection. | 2017 | J. Gastroenterol. Hepatol. | pmid:27505301 |
| Yoon HY et al. | Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease. | 2017 | Int. J. Tuberc. Lung Dis. | pmid:28826448 |
| Ishiguro N et al. | Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients. | 2017 | PLoS ONE | pmid:28288170 |
| Attaran B et al. | Effect of biofilm formation by clinical isolates of on the efflux-mediated resistance to commonly used antibiotics. | 2017 | World J. Gastroenterol. | pmid:28275296 |
| Berni E et al. | Risk of cardiovascular events, arrhythmia and all-cause mortality associated with clarithromycin versus alternative antibiotics prescribed for respiratory tract infections: a retrospective cohort study. | 2017 | BMJ Open | pmid:28115334 |
| Yoon H et al. | Eradication Downregulates Cellular Inhibitor of Apoptosis Protein 2 in Gastric Carcinogenesis. | 2017 | Gut Liver | pmid:27282269 |
| Costa S et al. | Efficacy and tolerability of culture-guided treatment for Helicobacter pylori infection. | 2017 | Eur J Gastroenterol Hepatol | pmid:28877088 |
| Pryjma M et al. | Antagonism between Front-Line Antibiotics Clarithromycin and Amikacin in the Treatment of Mycobacterium abscessus Infections Is Mediated by the Gene. | 2017 | Antimicrob. Agents Chemother. | pmid:28874379 |
| Santos RP et al. | induced rash and mucositis: a recently described entity. | 2017 | BMJ Case Rep | pmid:28830900 |
| Takahashi C et al. | Morphological study of efficacy of clarithromycin-loaded nanocarriers for treatment of biofilm infection disease. | 2017 | Med Mol Morphol | pmid:27119723 |
| Kwon S et al. | [The Efficacy of Moxifloxacin-containing Triple Therapy after Hybrid Therapy Failure in Eradication]. | 2017 | Korean J Gastroenterol | pmid:28830132 |
| Nanishi E et al. | Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study. | 2017 | J Am Heart Assoc | pmid:28684643 |
| Boal Carvalho P et al. | Randomized Controlled Trial for Helicobacter pylori Eradication in a Naive Portuguese Population: Is Sequential Treatment Superior to Triple Therapy in Real World Clinical Setting? | 2017 | Acta Med Port | pmid:28550827 |
| Shah SA et al. | Clarithromycin inhibits TNF-α-induced MUC5AC mucin gene expression via the MKP-1-p38MAPK-dependent pathway. | 2017 | Int. Immunopharmacol. | pmid:28550735 |
| Osaki T et al. | Usefulness of detection of clarithromycin-resistant Helicobacter pylori from fecal specimens for young adults treated with eradication therapy. | 2017 | Helicobacter | pmid:28544222 |
| Chang CT et al. | Antibiotic treatment of zebrafish mycobacteriosis: tolerance and efficacy of treatments with tigecycline and clarithromycin. | 2017 | J. Fish Dis. | pmid:28422304 |
| Furuya H et al. | SAPHO syndrome-like presentation of disseminated nontuberculous mycobacterial infection in a case with neutralizing anti-IFNγ autoantibody. | 2017 | Rheumatology (Oxford) | pmid:28371927 |
| Jakubů V et al. | Trends in the Minimum Inhibitory Concentrations of Erythromycin, Clarithromycin, Azithromycin, Ciprofloxacin, and Trimethoprim/Sulfamethoxazole for Strains of Bordetella pertussis isolated in the Czech Republic in 1967-2015. | 2017 | Cent. Eur. J. Public Health | pmid:29346850 |
| Ruiter R et al. | Helicobacter pylori resistance in the Netherlands: a growing problem? | 2017 | Neth J Med | pmid:29219812 |
| Vaz AM et al. | Capsule endoscopy in the diagnosis of disseminated complex infection. | 2017 | BMJ Case Rep | pmid:29167222 |
| Lee H et al. | Concomitant, sequential, and 7-day triple therapy in first-line treatment of Helicobacter pylori infection in Korea: study protocol for a randomized controlled trial. | 2017 | Trials | pmid:29149904 |
| Ye JF et al. | Evaluation of first-line bismuth-containing 7-day concomitant quintuple therapy for Helicobacter pylori eradication. | 2017 | J Dig Dis | pmid:29119724 |
| Painsi C and Lange-Asschenfeldt B | Image Gallery: Pink papules within a tattoo linked to Mycobacterium chelonae infection. | 2017 | Br. J. Dermatol. | pmid:28731256 |
| Fremlin GA et al. | Clarithromycin, rifampicin and fusidic acid triple combination therapy for chronic folliculocentric pustulosis of the scalp. | 2017 | Clin. Exp. Dermatol. | pmid:28691163 |
| Andere NMRB et al. | Clarithromycin as an Adjunct to One-Stage Full-Mouth Ultrasonic Periodontal Debridement in Generalized Aggressive Periodontitis: A Randomized Controlled Clinical Trial. | 2017 | J. Periodontol. | pmid:28671507 |
| Sotto RB et al. | Sub-lethal pharmaceutical hazard tracking in adult zebrafish using untargeted LC-MS environmental metabolomics. | 2017 | J. Hazard. Mater. | pmid:28623724 |
| Liatsos C and Leontiadis GII | The "report card" to grade H. Pylori treatment regimens: is it achievable in real-world in areas with high clarithromycin resistance? | 2017 | J Gastrointestin Liver Dis | pmid:28617893 |
| Chew CA et al. | The diagnosis and management of H. pylori infection in Singapore. | 2017 | Singapore Med J | pmid:28536725 |
| Adachi T et al. | Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for Helicobacter pylori. | 2017 | Oncology | pmid:29258111 |
| Moon SH et al. | Novel Linear Lipopeptide Paenipeptins with Potential for Eradicating Biofilms and Sensitizing Gram-Negative Bacteria to Rifampicin and Clarithromycin. | 2017 | J. Med. Chem. | pmid:29136469 |
| Carneiro MDS et al. | Lack of association between rrl and erm(41) mutations and clarithromycin resistance in Mycobacterium abscessus complex. | 2017 | Mem. Inst. Oswaldo Cruz | pmid:29091138 |
| Oikawa R et al. | Enrichment of Helicobacter pylori mutant strains after eradication therapy analyzed by gastric wash-based quantitative pyrosequencing. | 2017 | Tumour Biol. | pmid:28990461 |
| Feng L et al. | Removal of antibiotics during the anaerobic digestion of pig manure. | 2017 | Sci. Total Environ. | pmid:28628813 |
| Mougari F et al. | Selection of Resistance to Clarithromycin in Mycobacterium abscessus Subspecies. | 2017 | Antimicrob. Agents Chemother. | pmid:27799212 |
| O'Brien CR et al. | Feline leprosy due to Candidatus 'Mycobacterium tarwinense':Further clinical and molecular characterisation of 15 previously reported cases and an additional 27 cases | 2017 | J. Feline Med. Surg. | pmid:28438086 |
| Tan B et al. | Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial. | 2017 | PLoS ONE | pmid:28407007 |
| Freyne B and Curtis N | Mycobacterium gordonae Skin Infection in an Immunocompetent Child. | 2017 | Pediatr. Infect. Dis. J. | pmid:28403059 |
| Bustamante-Rengifo JA et al. | Effect of treatment failure on the CagA EPIYA motif in strains from Colombian subjects. | 2017 | World J. Gastroenterol. | pmid:28373764 |
| Marin AC et al. | Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis. | 2017 | Drugs | pmid:28361211 |
| Holmberg LA et al. | Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin. | 2017 | Acta Haematol. | pmid:28355602 |
| Smith S et al. | The Irish Helicobacter pylori Working Group consensus for the diagnosis and treatment of H. pylori infection in adult patients in Ireland. | 2017 | Eur J Gastroenterol Hepatol | pmid:28350745 |
| Mougari F et al. | Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria. | 2017 | J. Antimicrob. Chemother. | pmid:28333340 |
| Anwar HF et al. | Synthesis of clarithromycin ketolides chemically modified at the unreactive C10-methyl group. | 2017 | Bioorg. Med. Chem. | pmid:28302508 |
| Chang JY et al. | Triple therapy versus sequential therapy for the first-line Helicobacter pylori eradication. | 2017 | BMC Gastroenterol | pmid:28109257 |
| Sasaoka Y et al. | Neonatal apnea with Chlamydia pneumoniae infection. | 2017 | Pediatr Int | pmid:28102626 |
| Lapa GB et al. | Two approaches to the use of benzo[c][1,2]oxaboroles as active fragments for synthetic transformation of clarithromycin. | 2017 | J Enzyme Inhib Med Chem | pmid:28097898 |
| Chen PY et al. | Letter: levofloxacin resistance - a challenge for treatment of Helicobacter pylori infection. Authors' reply. | 2017 | Aliment. Pharmacol. Ther. | pmid:28074519 |
| Zamani M et al. | Letter: levofloxacin resistance - a challenge for the treatment of Helicobacter pylori infection. | 2017 | Aliment. Pharmacol. Ther. | pmid:28074507 |
| Chey WD et al. | ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. | 2017 | Am. J. Gastroenterol. | pmid:28071659 |
| Fernández Martos R et al. | Acute psychotic episode secondary to Helicobacter pylori eradication treatment. | 2017 | Rev Esp Enferm Dig | pmid:28071063 |
| Ko J et al. | Delayed onset Mycobacterium intracellulare keratitis after laser in situ keratomileusis: A case report and literature review. | 2017 | Medicine (Baltimore) | pmid:29390522 |
| Takeuchi S et al. | Hypotension induced by the concomitant use of a calcium-channel blocker and clarithromycin. | 2017 | BMJ Case Rep | pmid:28069789 |
| Kasai C et al. | Changes in plasma ghrelin and leptin levels in patients with peptic ulcer and gastritis following eradication of Helicobacter pylori infection. | 2016 | BMC Gastroenterol | pmid:27716077 |
| Gisbert JP | Helicobacter pylori-related diseases. | 2016 | Gastroenterol Hepatol | pmid:27888863 |
| Orrin E et al. | Sporotrichoid Mycobacterium chelonae. | 2016 | Australas. J. Dermatol. | pmid:27469486 |
| Yamamoto K et al. | Clarithromycin prevents human respiratory syncytial virus-induced airway epithelial responses by modulating activation of interferon regulatory factor-3. | 2016 | Pharmacol. Res. | pmid:27468646 |
| Ferro BE et al. | Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection. | 2016 | Antimicrob. Agents Chemother. | pmid:27458221 |
| Kuo CH et al. | A Rapid and Accurate Method to Evaluate Helicobacter pylori Infection, Clarithromycin Resistance, and CYP2C19 Genotypes Simultaneously From Gastric Juice. | 2016 | Medicine (Baltimore) | pmid:27227911 |
| Sluch IM et al. | Mycobacterium chelonae Scleral Abscess After Intravitreal Ranibizumab Injection. | 2016 | Cornea | pmid:27227391 |
| Xu J et al. | Preparation, characterization and pharmacokinetics evaluation of clarithromycin-loaded Eudragit(®) L-100 microspheres. | 2016 | Eur J Drug Metab Pharmacokinet | pmid:25652786 |
| Buchicchio A et al. | Biodegradation of carbamazepine and clarithromycin by Trichoderma harzianum and Pleurotus ostreatus investigated by liquid chromatography - high-resolution tandem mass spectrometry (FTICR MS-IRMPD). | 2016 | Sci. Total Environ. | pmid:27039063 |
| Melia MT and Auwaerter PG | Time for a Different Approach to Lyme Disease and Long-Term Symptoms. | 2016 | N. Engl. J. Med. | pmid:27028918 |
| Berende A et al. | Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease. | 2016 | N. Engl. J. Med. | pmid:27028911 |
| D'Erme AM et al. | Successful treatment of rosacea fulminans in a 59-year-old woman with macrolide antibiotics and prednisone. | 2016 | Int. J. Dermatol. | pmid:27028670 |
| Niv Y | Doxycycline in Eradication Therapy of Helicobacter pylori--a Systematic Review and Meta-Analysis. | 2016 | Digestion | pmid:26849820 |
| Song Z et al. | Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy. | 2016 | Dig Liver Dis | pmid:26847964 |
| Konstantinidis T et al. | Immunomodulatory Role of Clarithromycin in Acinetobacter baumannii Infection via Formation of Neutrophil Extracellular Traps. | 2016 | Antimicrob. Agents Chemother. | pmid:26643338 |
| Ferro BE et al. | Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin. | 2016 | Antimicrob. Agents Chemother. | pmid:26643335 |
| Wu TS et al. | Postcesarean section wound infection caused by Mycobacterium massiliense. | 2016 | J Microbiol Immunol Infect | pmid:26350122 |
| Senatore FJ et al. | Helicobacter pylori treatment: Still a work in progress. | 2016 | Postgrad Med | pmid:26490697 |
| Narita M et al. | Antimicrobial Susceptibility of Microorganisms Isolated from Periapical Periodontitis Lesions. | 2016 | Bull. Tokyo Dent. Coll. | pmid:27665691 |
| Ghaith D et al. | Mutations affecting domain V of the 23S rRNA gene in Helicobacter pylori from Cairo, Egypt. | 2016 | J Chemother | pmid:26358218 |